A $2.5mn, two-year initiative backed by the US Agency for International Development (USAID) will aim to raise regulatory standards and boost production capacity in Uzbekistan's pharmaceutical industry, the US Embassy in Tashkent has announced.
US Ambassador to Uzbekistan, Jonathan Henick, together with Uzbek health ministry officials and the Agency for Development of the Pharmaceutical Industry, inaugurated the programme, entitled Diversifying Asia’s Pharmaceutical Supply Chain.
Presently, Uzbekistan is home to more than 220 private pharmaceutical entities, contributing approximately 45% of the country's medicinal output. The government wants to raise the percentage to 80% by 2026.
Speaking at the launch event, Henick said: “Through our partnership, we will improve the health of the people of Uzbekistan while also improving the strength and responsiveness of the public and private pharmaceutical sectors.
"By aligning with global standards, we not only protect patients but also boost trust in local medicines, pharmaceutical companies, pharmacists, and the healthcare system as a whole."
A core project objective is securing assurance that medicines manufactured in Uzbekistan adhere to stringent quality benchmarks.
"Medicines that are not manufactured properly may harm patients directly or fail to treat their underlying diseases," noted Henick.
The Eurasian Development Bank (EDB) said on March 26 it had fully redeemed a five-year Eurobond, meeting all obligations to investors at maturity. The bank paid a total of €286mn, covering both ... more
London-listed TBC Bank Group PLC (LON: TBCG) is weighing up conducting a separate initial public offering (IPO) for its TBC Uzbekistan digital bank business. Reuters on February 24 ... more
Indian budget carrier IndiGo has cancelled all flights to and from Tbilisi, Almaty, Baku and Tashkent until February 28 due to the developing situation around Iran, the airline announced on February ... more